,"The U.S. FDA has announced a virtual meeting of the Tobacco Products Scientific Advisory Committee (TPSAC) on January 22, 2026, to evaluate modified risk tobacco product (MRTP) applications submitted by Swedish Match USA for 20 ZYN nicotine pouch products. These products—previously authorized under the PMTA pathway in January 2025—are now seeking approval to market with a reduced-risk claim stating that using ZYN instead of cigarettes lowers the risk of several major diseases, including mouth cancer, lung cancer, heart disease, stroke, emphysema, and chronic bronchitis.
TPSAC will review scientific evidence on relative health risks, consumer understanding of the proposed claim, and potential population-level impacts before advising FDA. The meeting will be open to the public, with opportunities for written comments (Docket No. FDA-2025-N-0835) until January 21, 2026, and oral presentations on January 22 for those who register by December 31, 2025. FDA has also posted redacted MRTP application materials and will consider all relevant evidence, public comments, and TPSAC recommendations before issuing a final decision."